Brian McNeil Cochran is an accomplished inventor based in Thousand Oaks, California. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of four patents to his name.

Latest Patents

Cochran's latest innovations include the synthesis of a key intermediate for a KRAS G12C inhibitor compound. This invention offers an improved, efficient, and scalable process for preparing intermediate compounds, particularly focusing on those that target KRAS G12C mutations. Another notable patent relates to the processes for making crystalline forms of a MDM2 inhibitor. This invention elaborates on the production of 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid, along with its intermediates and procedures for their creation.

Career Highlights

Cochran works for Amgen Inc., a leading biotechnology company known for its innovative approaches to drug development. Over his career, he has focused on advancing pharmaceutical compounds that can address critical health issues.

Collaborations

Throughout his tenure at Amgen, Brian has collaborated with esteemed coworkers such as Matthew Bio and Sebastien Caille. His collaborations have played a significant role in enhancing the effectiveness and efficiency of the research processes.

Conclusion

Brian McNeil Cochran exemplifies the pioneering spirit of innovation in the pharmaceutical industry. His patents and collaborations reflect not only his expertise but also his commitment to developing solutions that can potentially transform patient care and treatment.